Home › Trials › NCT05226871

Continuing treatment for patients benefiting from palbociclib

A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED PALBOCICLIB CLINICAL STUDIES

PHASE2 · Pfizer · NCT05226871

This study is testing if continuing treatment with palbociclib and other medications can help people with advanced breast cancer and head and neck cancer who have already benefited from it.

Quick facts

PhasePHASE2
Study typeInterventional
Enrollment35 (estimated)
Ages18 Years and up
SexAll
SponsorPfizer (industry)
Locations22 sites (San Francisco, California and 21 other locations)
Trial IDNCT05226871 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to provide ongoing treatment with palbociclib and other medications for participants who have shown clinical benefit in a previous Pfizer-sponsored study. It is an open-label, Phase 2 trial where eligible patients will continue their treatment regimen while being monitored for safety and efficacy. Participants must comply with scheduled visits and treatment plans, and their experiences will be evaluated to ensure the safety of the study medications. The study focuses on patients with advanced breast cancer and head and neck cancer.

Who should consider this trial

Good fit: Ideal candidates are patients who have benefited from previous treatment with palbociclib in a Pfizer-sponsored study.

Not a fit: Patients who are not deriving clinical benefit from the parent study or have medical reasons preventing their inclusion will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide continued access to effective treatments for patients with advanced cancers.

How similar studies have performed: Other studies involving palbociclib have shown promising results, indicating that this approach is built on previously successful methodologies.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Any participant who is receiving study treatment and deriving clinical benefit as determined by the investigator in a Pfizer-sponsored palbociclib Parent Study
* Participants must agree to follow the reproductive criteria
* Participants who are willing and able to comply with all scheduled visits, treatment plans, and other study procedures
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document and protocol

Exclusion Criteria:

* Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study

Where this trial is running

San Francisco, California and 21 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Breast Cancer, Head and Neck Cancer, Hormone Receptor Positive Advanced Breast Cancer, Squamous Cell Carcinoma of the Head and Neck

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.